TerminatedPhase 3NCT03403205

Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease

Studying Wilson disease

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Alexion Pharmaceuticals, Inc.
Principal Investigator: Eugene S. Swenson, M.D., Ph.D.
Alexion Pharmaceuticals, Inc.
Intervention: ALXN1840(drug)
Enrollment: 214 enrolled
Eligibility: 12 years · All sexes
Timeline: 2018 – 2023

Study locations (30)

Research Site, Los Angeles, California, United States
Research Site, New Haven, Connecticut, United States
Research Site, Chicago, Illinois, United States
Research Site, Ann Arbor, Michigan, United States
Research Site, Houston, Texas, United States
Research Site, Seattle, Washington, United States
Research Site, Adelaide, Australia
Research Site, Concord, Australia
Research Site, Parkville, Australia
Research Site, Graz, Austria
Research Site, Innsbruck, Austria
Research Site, Vienna, Austria
Research Site, Toronto, Ontario, Canada
Research Site, Prague, Czechia
Research Site, Århus N, Denmark
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03403205 on ClinicalTrials.gov

Other trials for Wilson disease

Additional recruiting or active studies for the same condition.

See all trials for Wilson disease →

← Back to all trials